CClinicalTrials.gg
CompletedNCT05054504FAB-IQUpdated Apr 9, 2024

Feasibility and Acceptability of Butterfly iQ

An interventional study of Butterfly iQ in Pregnancy Related, sponsored by Jhpiego. Completed at 1 site in Malawi. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-09.

Sponsored by Jhpiego · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
1,575
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to investigate feasibility and acceptability of a novel intervention to integrate Butterfly IQ into antenatal care (ANC) service delivery in Malawi. The study will also explore potential impact of the intervention on selected service delivery outcomes and identification of abnormal pregnancies.

Read the detailed description

The purpose of this study is to investigate the feasibility and acceptability of a novel intervention to integrate Butterfly IQ into ANC service delivery in Blantyre, Malawi. This study will further the understanding of antenatal ultrasound in Malawi by testing the following hypothesis:

When planned and implemented collaboratively with local stakeholders, limited introduction and integration of point-of-care ultrasound with Butterfly iQ into ANC service delivery at health center level will be feasible and acceptable for health providers and clients.

The study intervention will include a multi-phased approach to design, introduction, improvement, and evaluation of Butterfly IQ for routine obstetric ultrasound integrated into ANC service delivery in Malawi.

Phase 1: Training Phase 1 includes training on Butterfly IQ, integration in ANC workflow, and referral/counter-referral within network.

Phase 2: Iterative Service Delivery Phase 2 includes weekly evaluation and iterative re-design of services.

Phase 3: Final Evaluation Phase 3 includes evaluation for potential integration into current policies and frameworks; determination to pursue pending additional factors; or determination of incompatibility, as well as selected support for transition/handover, if applicable.

02

Conditions studied

  • Pregnancy Related

Keywords

  • Butterfly IQ
  • Malawi
  • Blantyre
  • Antenatal care
  • ANC/PNC Research Collective
  • Point of care ultrasound
  • Bill & Melinda Gates Foundation
  • Johns Hopkins Research Project
  • Johns Hopkins Bloomberg School of Public Health
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Eligibility criteria by phase and participant type

Phase 1 Inclusion Criteria

  1. Member of HC or hospital staff providing obstetric care.
  2. Able and willing to comply with all study requirements and complete all study procedures.
  3. Able and willing to provide informed consent to be screened for and to take part in the study.

Phase 1 Exclusion Criteria 1. Has any condition that, in the opinion of the investigator/designee, would preclude informed consent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.

Phase 2 Inclusion Criteria

Study Participant - Health Center and Hospital Staff:

  1. Member of HC or hospital staff providing obstetric care.
  2. Able and willing to comply with all study requirements and complete all study procedures.
  3. Able and willing to provide informed consent to be screened for and to take part in the study.

Study Participant - ANC Clients:

Participants must meet all criteria to be eligible for inclusion in the study:

  1. Age 18 years or older at Screening, as verified per site Standard Operating Procedures (SOPs).
  2. At enrollment, present for first ANC visit.
  3. Able and willing to comply with all study requirements and complete all Phase 2 study procedures.
  4. Able and willing to provide informed consent to be screened for and to take part in Phase 2 of the study.
  5. Intention to stay within study catchment area for study Phase 2 duration and willingness to give adequate locator information, as defined in site SOPs.

Phase 2 Exclusion Criteria

Study Participant - Health Center and Hospital Staff:

  1. Has any condition that, in the opinion of the investigator/designee, would preclude informed consent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.

Study participant - ANC Clients:

  1. Has any condition that, in the opinion of the investigator/designee, would preclude informed consent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives

Phase 3 Inclusion Criteria

  1. Participated in Phase 1 or 2 of the study or newly recruited stakeholder interested in development or implementation of obstetric ultrasound in Malawi.
  2. Able and willing to comply with all study requirements and complete all Phase 3 study procedures.
  3. Able and willing to provide informed consent to be screened for and to take part in Phase 3 of the study.

Phase 3 Exclusion Criteria

  1. Has any condition that, in the opinion of the investigator/designee, would preclude informed consent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives
04

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,575 participants (actual)

Study arms

  • Other
    Intervention

    The primary intervention is a multi-phase, mixed methods, implementation research study that will investigate the feasibility and acceptability of the limited introduction of ultrasound via the Butterfly iQ device into routine ANC service delivery at health center level in Blantyre, Malawi. The study will occur in three phases: 1) Training, 2) Iterative Service Delivery, and 3) Final Evaluation.

    Device: Butterfly iQ

Interventions

  • DeviceButterfly iQ

    The primary intervention under study is the Butterfly iQ point-of-care ultrasound device, embedded in a larger program of training, iterative ANC service delivery design, and a final program evaluation.

05

What researchers measure

Primary outcomes

  1. Feasibility of the intervention by participant report

    Proportion of enrolled midwives who report the intervention to be feasible

    Time frame: 7 months

  2. Feasibility of the intervention by quality standards met (ultrasound)

    Proportion of ultrasound examinations found to meet quality standards

    Time frame: 7 months

  3. Feasibility of the intervention by quality standards met (ANC)

    Proportion of ANC visits (that included Butterfly IQ) found to meet quality standards

    Time frame: 7 months

  4. Feasibility of the intervention by observation of functioning systems

    Proportion of Butterfly IQ systems functioning at end of study period

    Time frame: 7 months

  5. Feasibility of the intervention by observation of environments of care

    Proportion of participating HC with facilitative environments of care

    Time frame: 7 months

Secondary outcomes

  1. Acceptability, by participant report (providers)

    Proportion of providers who find the intervention acceptable

    Time frame: 7 months

  2. Acceptability, by participant report (ANC clients)

    Proportion of ANC clients who find the intervention acceptable

    Time frame: 7 months

Other outcomes

  1. Gestational age at first ANC contact

    Median gestational age at first ANC contact

    Time frame: 7 months

  2. Number and types of suspected and confirmed higher-risk conditions identified by ultrasound and recorded in study records

    Numbers of the following * Ectopic pregnancy * Multiple gestation * Abnormal placentation * Intrauterine fetal demise * Abnormalities of amniotic fluid, e.g., oligohydramnios, polyhydramnios * Fetal anomaly * Other condition not specified above

    Time frame: 7 months

06

Study locations

1 site
  • Johns Hopkins Research Project
    Blantyre, Malawi
07

Registry details

Key details

Study ID
NCT05054504
Lead sponsor
Jhpiego
Collaborators
Bill and Melinda Gates Foundation, Johns Hopkins Bloomberg School of Public Health, Kamuzu University of Health Sciences, Ministry of Health, Malawi
Responsible party
Sponsor
First posted
Sep 23, 2021
Start date
Oct 6, 2021
Primary completion
Mar 15, 2024
Completion
Mar 15, 2024
Last update
Apr 9, 2024

Study contacts

Lisa M Noguchi, PhD, MSN
study director · Jhpiego, Johns Hopkins University
Linly Seyama
principal investigator · University of Malawi College of Medicine, JHP Blantyre

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion